KALV vs REGN · rev $13.7M vs P/E 14, rev $4.29B
Kalvista Pharmaceuticals Inc (KALV) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Kalvista Pharmaceuticals Inc (KALV) is a biotechnology company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US. It is led by Leonard S. Schleifer M.D., Ph.D..
Latest reported KALV revenue for 2025-09-30 was $13.7M. Net income was -$158.9M. KALV currently screens at market cap $1.44B.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
KALV currently screens at market cap $1.44B. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the KALV and REGN stock pages for the full models.
Not investment advice.